Herpes Treatment Market size to grow by USD 723.04 Mn | Market Research Insights highlight increasing prevalence of herpes infection as Key Driver | Technavio

NEW YORK, June 28, 2022 /PRNewswire/ -- According to the research report "Herpes Treatment Market by Type and Geography - Forecast and Analysis", the market will witness a YOY growth of 5.97% at a CAGR of 3.4% during the forecast period. The report is segmented by type (herpes zoster and herpes simplex) and geography (North America, Europe, Asia, and ROW).

For more insights on YOY and CAGR, Read the Sample Report

The global Herpes Treatment Market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. 

The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Some vendors are also adopting inorganic growth strategies such as M&As to remain competitive in the market.?  

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

• Bausch Health Companies Inc.
• Cipla Inc.
• Eli Lilly and Co.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Maruho Co. Ltd.
• Merck and Co. Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc. 

Find additional highlights on the growth strategies adopted by vendors and their product offerings, Get Sample Report. 

North America will account for 41% of market growth. In North America, the US is the primary market for herpes medications. The market in this region will expand more slowly than the market in Asia. Over the course of the projection period, the presence of a sizable patient base will support the expansion of the herpes treatment market in North America.

Furthermore, countries such as the US, Japan, Germany, France, and the UK are expected to emerge as prominent markets for Herpes Treatment Market during the forecast period. 

Know more about this market's geographical distribution along with a detailed analysis of the top regions. Buy the Sample Report Now!

The herpes zoster segment's market share growth for herpes treatments will be high. The herpes zoster market is anticipated to increase at a faster rate than average during the projected period due to the rising prevalence of the disease and anticipated therapeutic launches for its treatment. Herpes zoster instances are on the rise for a variety of reasons, including an increase in the elderly population and the number of immunocompromised individuals.

View Sample: to know additional highlights and key points on various market segments and their impact in coming years. 

Technavio categorizes the global herpes treatment market as part of the global pharmaceuticals market within the global health care market. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the global pharmaceuticals market includes the following core components:

• Inputs
• Inbound logistics
• Operations
• Outbound logistics
• Marketing and sales
• Service
• Support activities
• Innovation

Click Here for Sample Report for highlights on Parent Market Analysis and Value Chain Analysis affecting the Herpes Treatment Market. 

Don't miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.  

Do reach out to our analysts for more customized reports as per your requirements. Speak to an Analyst Now!   

Rare Hemophilia Factors Market by Method and Geography - Forecast and Analysis 2022-2026

Vaginal Speculum Market by Application and Geography - Forecast and Analysis 2022-2026

1 Executive Summary

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 01: Parent market
• Exhibit 02: Market characteristics

• 2.2 Value chain analysis
• Exhibit 03: Value chain analysis

3 Market Sizing

• 3.1 Market definition
• Exhibit 04: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 05: Market segments

• 3.3 Market size 2020

• 3.4 Market outlook: Forecast for 2020 - 2025
• Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
• Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 08: Five forces analysis 2020 & 2025

• 4.2 Bargaining power of buyers
• Exhibit 09: Bargaining power of buyers

• 4.3 Bargaining power of suppliers
• Exhibit 10: Bargaining power of suppliers

• 4.4 Threat of new entrants
• Exhibit 11: Threat of new entrants

• 4.5 Threat of substitutes
• Exhibit 12: Threat of substitutes

• 4.6 Threat of rivalry
• Exhibit 13: Threat of rivalry

• 4.7 Market condition
• Exhibit 14: Market condition - Five forces 2020

5 Market Segmentation by Type

• 5.1 Market segments
• Exhibit 15: Type - Market share 2020-2025 (%)

• 5.2 Comparison by Type
• Exhibit 16: Comparison by Type

• 5.3 Herpes zoster - Market size and forecast 2020-2025
• Exhibit 17: Herpes zoster - Market size and forecast 2020-2025 ($ million)
• Exhibit 18: Herpes zoster - Year-over-year growth 2020-2025 (%)

• 5.4 Herpes simplex - Market size and forecast 2020-2025
• Exhibit 19: Herpes simplex - Market size and forecast 2020-2025 ($ million)
• Exhibit 20: Herpes simplex - Year-over-year growth 2020-2025 (%)

• 5.5 COVID-19 impact and recovery for the segment

• 5.6 Market opportunity by Type
• Exhibit 21: Market opportunity by Type

6 Customer landscape

• 6.1 Customer landscape
• Exhibit 22: Customer landscape

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 23: Market share by geography 2020-2025 (%)

• 7.2 Geographic comparison
• Exhibit 24: Geographic comparison

• 7.3 North America - Market size and forecast 2020-2025
• Exhibit 25: North America - Market size and forecast 2020-2025 ($ million)
• Exhibit 26: North America - Year-over-year growth 2020-2025 (%)

• 7.4 Europe - Market size and forecast 2020-2025
• Exhibit 27: Europe - Market size and forecast 2020-2025 ($ million)
• Exhibit 28: Objectives of European Patients' Forum
• Exhibit 29: Europe - Year-over-year growth 2020-2025 (%)

• 7.5 Asia - Market size and forecast 2020-2025
• Exhibit 30: Asia - Market size and forecast 2020-2025 ($ million)
• Exhibit 31: Asia - Year-over-year growth 2020-2025 (%)

• 7.6 ROW - Market size and forecast 2020-2025
• Exhibit 32: ROW - Market size and forecast 2020-2025 ($ million)
• Exhibit 33: ROW - Year-over-year growth 2020-2025 (%)

• 7.7 Key leading countries
• Exhibit 34: Key leading countries

• 7.8 Market opportunity by geography
• Exhibit 35: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges
• Exhibit 36: Impact of drivers and challenges

• 8.3 Market trends

9 Vendor Landscape

• 9.1 Competitive scenario

• 9.2 Vendor landscape
• Exhibit 37: Vendor landscape

• 9.3 Landscape disruption
• Exhibit 38: Landscape disruption
• Exhibit 39: Industry risks

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 40: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 41: Market positioning of vendors

• 10.3 Bausch Health Companies Inc.

• 10.4 Cipla Inc.
• Exhibit 47: Cipla Inc. - Overview
• Exhibit 48: Cipla Inc. - Business segments
• Exhibit 49: Cipla Inc. - Key news
• Exhibit 50: Cipla Inc. - Key offerings
• Exhibit 51: Cipla Inc. - Segment focus

• 10.5 Eli Lilly and Co.
• Exhibit 52: Eli Lilly and Co. - Overview
• Exhibit 53: Eli Lilly and Co. - Business segments
• Exhibit 54: Eli Lilly and Co. - Key news
• Exhibit 55: Eli Lilly and Co. - Key offerings
• Exhibit 56: Eli Lilly and Co. - Segment focus

• 10.6 Gilead Sciences Inc.
• Exhibit 57: Gilead Sciences Inc. - Overview
• Exhibit 58: Gilead Sciences Inc. - Product and service
• Exhibit 59: Gilead Sciences Inc. - Key news
• Exhibit 60: Gilead Sciences Inc. - Key offerings

• 10.7 GlaxoSmithKline Plc
• Exhibit 61: GlaxoSmithKline Plc - Overview
• Exhibit 62: GlaxoSmithKline Plc - Business segments
• Exhibit 63: GlaxoSmithKline Plc - Key news
• Exhibit 64: GlaxoSmithKline Plc - Key offerings
• Exhibit 65: GlaxoSmithKline Plc - Segment focus

• 10.8 Maruho Co. Ltd.
• Exhibit 66: Maruho Co. Ltd. - Overview
• Exhibit 67: Maruho Co. Ltd. - Product and service
• Exhibit 68: Maruho Co. Ltd. - Key news
• Exhibit 69: Maruho Co. Ltd. - Key offerings

• 10.9 Merck and Co. Inc.
• Exhibit 70: Merck and Co. Inc. - Overview
• Exhibit 71: Merck and Co. Inc. - Business segments
• Exhibit 72: Merck and Co. Inc. - Key news
• Exhibit 73: Merck and Co. Inc. - Key offerings
• Exhibit 74: Merck and Co. Inc. - Segment focus

• 10.10 Novartis AG
• Exhibit 75: Novartis AG - Overview
• Exhibit 76: Novartis AG - Business segments
• Exhibit 77: Novartis AG - Key news
• Exhibit 78: Novartis AG - Key offerings
• Exhibit 79: Novartis AG - Segment focus

• 10.11 Teva Pharmaceutical Industries Ltd.
• Exhibit 80: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 81: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 82: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 83: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 84: Teva Pharmaceutical Industries Ltd. - Segment focus

• 10.12 Viatris Inc.
• Exhibit 85: Viatris Inc. - Overview
• Exhibit 86: Viatris Inc. - Business segments
• Exhibit 87: Viatris Inc. - Key news
• Exhibit 88: Viatris Inc. - Key offerings
• Exhibit 89: Viatris Inc. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Currency conversion rates for US$
• Exhibit 90: Currency conversion rates for US$

• 11.3 Research methodology
• Exhibit 91: Research Methodology
• Exhibit 92: Validation techniques employed for market sizing
• Exhibit 93: Information sources

• 11.4 List of abbreviations
• Exhibit 94: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. 

Contact 
Technavio Research 
Jesse Maida 
Media & Marketing Executive 
US: +1 844 364 1100 
UK: +44 203 893 3200 
Email:?[email protected] 
Website:?www.technavio.com/ 

SOURCE Technavio